Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2
A team of researchers from Spain and Canada recently characterized the antibody kinetics and neutralization capacity at 4 cross-sectional surveys between March and October 2020 and determined the seroprevalence in the same cohort of healthcare workers.